InsidersTradesSigma
MoonLake Immunotherapeutics Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the MoonLake Immunotherapeutics share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, MoonLake Immunotherapeutics has recorded 32 insider filings. Market capitalisation: €1.6bn. The latest transaction was filed on 23 June 2026 (Cession). Among the most active insiders: Bodenstedt Matthias. Every trade is accessible without an account.
32
Insider Decl.
0
Thresholds
€52m
5 ops.
Buy Volume
€112m
16 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate MoonLake Immunotherapeutics Buy (bullish), based on 13 analysts. Average price target: US$28.00.
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 23 June 2026
Declarations32 total
39,120 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-071075:0
15,082 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-070259:0
2,794 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-070259:1
13,653 shares@ US$20.020.025% mcap50.0% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-055799:0
13,653 shares@ US$20.020.025% mcap50.0% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-055799
95,763 shares0Class A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-019672:0
95,763 shares0Class A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-019674:0
111,949 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-005686:0
1,030,589 shares@ US$50.001651.5% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-24-002263:0
171,000 shares@ US$53.72100.0% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-086271:0
836,862 shares@ US$50.001641.8% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-24-002263:1
132,549 shares@ US$50.00166.6% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-24-002263:2
62,810 shares@ US$55.0073.0% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-018675:0
29,491 shares@ US$55.0057.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-018671:0
1,125 shares@ US$55.271.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-016544:0
10,000 shares@ US$57.4520.4% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-016240:0
20,000 shares@ US$60.1825.7% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-015446:0
10,000 shares@ US$62.4222.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-24-014996:0
94,736 shares@ US$59.2291.7% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-23-097671:0
58,839 shares@ US$59.89736.4% of flowClass A Ordinary SharesSEC:0000929638-23-002739:0
Ideal exit: 1 Jul 2024 (T+270)
74,911 shares@ US$57.377.8% of flowClass A Ordinary SharesSEC:0000929638-23-002692:0
Ideal exit: 28 Jun 2024 (T+270)
62,972 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001013762-23-001300:0
2,527,477 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001013762-23-001295:0
3,027,483 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001013762-23-001297:0
342,980 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001013762-23-001303:0
25 of 32 declarations
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotechnology company based in the United States and listed on the NASDAQ market. Founded in 2021 by an international team of immunology specialists, the company has built its strategy around a single lead asset, sonelokimab (SLK), a tri-specific Nanobody® designed to target the IL-17A/IL-17F inflammatory pathway. While MoonLake’s operational headquarters are in Zug, Switzerland, it is still a U.S.-listed issuer that is closely followed by investors in growth healthcare and biotech. MoonLake’s business model is that of a development-stage company: it does not yet commercialize a product and instead focuses on clinical development, regulatory planning, and manufacturing readiness. The investment case is centered on SLK’s potential to become a differentiated therapy across inflammatory diseases with substantial unmet need, especially hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Management describes the strategy as a “pipeline within a product,” meaning one molecule being advanced across multiple related indications. From a competitive standpoint, MoonLake operates in therapeutic areas where biologic treatments already exist, but where response depth, durability, tolerability, and convenience remain key differentiators. The company positions SLK as an IL-17A/F-balanced inhibitor with the potential for deep tissue penetration and strong clinical activity in both skin and joint disease. That places MoonLake in direct competition with much larger dermatology and rheumatology franchises, but with a narrow, highly focused scientific profile that could create upside if clinical execution remains strong. Recent news has materially advanced the regulatory narrative. In January 2026, MoonLake said it received positive FDA feedback on its biologics license application strategy for HS, supporting a planned BLA submission in the second half of 2026. In February 2026, the FDA granted Fast Track designation to sonelokimab in PPP, improving the development pathway for that program. The company also released updated clinical data through 2025 and early 2026 across the VELA, MIRA, LEDA, S-OLARIS and IZAR programs, creating a busy catalyst calendar. For international investors, MoonLake remains a high-risk, high-upside biotech story driven by a single lead asset, rapid clinical execution, and a heavy dependence on future regulatory milestones.
